Sotagliflozin for treating type 2 diabetes [ID1657]
Proposed [GID-TA10665] Expected publication date: TBC
Search results
662 results
-
-
Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]
Proposed [GID-TA10332] Expected publication date: TBC
-
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154
Proposed [GID-TA10198] Expected publication date: TBC
-
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Proposed [GID-TA10336] Expected publication date: TBC
-
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)
Proposed [GID-TA10426] Expected publication date: TBC
-
Semaglutide for treating type 2 diabetes (ID1450)
Proposed [GID-TA10438] Expected publication date: TBC
-
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]
Proposed [GID-TA10297] Expected publication date: TBC
-
Pegvaliase for treating phenylketonuria [ID1110]
Proposed [GID-TA10345] Expected publication date: TBC
-
Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)
Proposed [GID-TA10239] Expected publication date: TBC
-
Rivaroxaban for treating chronic heart failure [ID1462]
Proposed [GID-TA10393] Expected publication date: TBC
-
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Proposed [GID-TA10715] Expected publication date: TBC
-
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Proposed [GID-TA10717] Expected publication date: TBC
-
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]
Proposed [GID-TA10718] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]
Proposed [GID-TA10707] Expected publication date: TBC
-
Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]
Proposed [GID-TA10709] Expected publication date: TBC
-
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Proposed [GID-TA10748] Expected publication date: TBC
-
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Proposed [GID-TA10750] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]
Proposed [GID-TA10751] Expected publication date: TBC
-
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Proposed [GID-TA10752] Expected publication date: TBC
-
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Proposed [GID-TA10745] Expected publication date: TBC
-
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Proposed [GID-TA10747] Expected publication date: TBC
-
Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]
Proposed [GID-TA10767] Expected publication date: TBC
-
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]
Proposed [GID-TA10768] Expected publication date: TBC
-
Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]
Proposed [GID-TA10770] Expected publication date: TBC
-
Foscarbidopa–foslevodopa for treating motor fluctuations in Parkinson's disease [ID3876]
Proposed [GID-TA10772] Expected publication date: TBC
-
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Proposed [GID-TA10773] Expected publication date: TBC
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Proposed [GID-TA10774] Expected publication date: TBC
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]
Proposed [GID-TA10775] Expected publication date: TBC
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Proposed [GID-TA10776] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Proposed [GID-TA10777] Expected publication date: TBC
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Proposed [GID-TA10778] Expected publication date: TBC
-
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Proposed [GID-TA10779] Expected publication date: TBC
-
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]
Proposed [GID-TA10535] Expected publication date: TBC
-
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Proposed [GID-TA10685] Expected publication date: TBC
-
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Proposed [GID-TA10662] Expected publication date: TBC
-
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Proposed [GID-TA10700] Expected publication date: TBC
-
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]
Proposed [GID-TA10676] Expected publication date: TBC
-
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Proposed [GID-TA10763] Expected publication date: TBC
-
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]
Proposed [GID-TA10666] Expected publication date: 26 August 2021
-
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]
Proposed [GID-TA10654] Expected publication date: TBC
-
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
Proposed [GID-TA10714] Expected publication date: TBC
-
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Proposed [GID-TA10727] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Proposed [GID-TA10728] Expected publication date: TBC
-
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
Proposed [GID-TA10730] Expected publication date: TBC
-
Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]
Proposed [GID-TA10739] Expected publication date: TBC
-
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
Proposed [GID-TA10536] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Proposed [GID-TA10757] Expected publication date: TBC
-
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]
Proposed [GID-TA10758] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Proposed [GID-TA10741] Expected publication date: TBC
-
Dapagliflozin for treating chronic kidney disease [ID3866]
Proposed [GID-TA10808] Expected publication date: TBC